Key Points {#FPar1}
==========

In this clinical trial, the test product containing acetaminophen 650 mg plus caffeine 65 mg was bioequivalent to the reference product containing only acetaminophen 650 mg, in the Mexican population.The absorption rate of acetaminophen was slightly faster in combination with caffeine, only in the first sample schedule; according to Renner et al., this might mean a better analgesic effect than monotherapy in the Mexican population.

Introduction {#Sec1}
============

In Mexico, there are currently more than 50 products containing acetaminophen, either alone or in combination with other drugs, in different doses and pharmaceutical forms. However, no pharmacokinetic studies regarding these products in the Mexican population are available in the scientific literature. Therefore, it is important to perform clinical trials to increase the knowledge on the bioavailability of this drug and its combinations in Mexican individuals.

Acetaminophen is an analgesic, antipyretic, and anti-inflammatory drug that inhibits cyclooxygenase, preventing the synthesis of prostaglandins \[[@CR1]--[@CR5]\]. Its mechanism of action is similar to aspirin; however, it does not affect platelet aggregation, exert cardiovascular effects, cause respiratory actions, or result in gastric damage \[[@CR1]--[@CR6]\]. The oral absorption of acetaminophen is fast and complete \[[@CR5]\]; meals reduce its final absorption, the volume of distribution is 0.95 ± 0.12 L/kg, it crosses the placental barrier, and it can appear in human milk. Acetaminophen has a low level of plasma protein binding (10--30 %) \[[@CR1]\]. Its hepatic metabolism is extensive (95 %) and presents a first-pass effect \[[@CR1], [@CR4], [@CR5], [@CR7]\]. The clearance of acetaminophen is 5 mL/min/kg, the renal excretion as unchanged drug is only 1--4 %, and the rest is eliminated as inactive metabolites. Its elimination half-life is between 2 and 3 h \[[@CR1]\].

Acetaminophen is used for the temporary relief of minor aches and pains associated with colds, headache, toothache, muscular aches, and backache. Additionally, it is used for minor arthritis pain, menstrual cramps, and for fever reduction \[[@CR8]\]. Acetaminophen 1000 mg is an effective and well-tolerated treatment for episodic and moderate migraine headache. In addition, it provides a beneficial effect on associated symptoms (nausea, photophobia, phonophobia, and functional disability) \[[@CR9]\]. Acetaminophen alone is not an effective therapy for acute migraine but is the first choice during pregnancy. The combination of an analgesic containing aspirin, caffeine, and acetaminophen is an effective first-line treatment for migraine \[[@CR10]\].

Caffeine is an effective adjuvant analgesic \[[@CR2]\] and potentiates the analgesic effect of acetaminophen (which alone requires a 40 % higher dose to reach a level of pain relief compared with that obtained with caffeine). Caffeine acts as a mild psycho-stimulant, being able to re-establish the alertness and performance capacity in subjects experiencing fatigue \[[@CR1], [@CR11]\]. The hepatic metabolism produces active metabolites (paraxanthine, theophylline, and theobromine) that contribute to pharmacologic effects \[[@CR1], [@CR11]--[@CR13]\]. Caffeine contributes to competitive inhibition of phosphodiesterase by inactivating the cyclic adenosine monophosphate. It also increases the permeability of calcium in the sarcoplasmatic reticulum and blocks the adenosine receptors, thereby increasing the activity of neurotransmitters such as acetylcholine, adrenaline, noradrenaline, dopamine, and glutamate \[[@CR1]\]. The oral absorption of caffeine is complete and fast, needing 1 h to reach the maximum plasma concentration (*t* ~max~). After an oral dose of 1 mg/kg, its bioavailability is 99 % and the peak serum concentration is 1--2 µg/mL \[[@CR1]\]. Its volume of distribution is 0.55 L/kg, reaching all tissues; thus, it crosses the blood--brain and placental barriers, is found in mother's milk, and only 35 % was bound to plasma proteins \[[@CR1]\]. Caffeine has a linear elimination, with an elimination half-life of approximately 5 h \[[@CR1]\].

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

The study was approved by the Research and Ethic Committees and the Federal Commission for the Sanitary Risk Protection of Mexico (Comisión Federal para la Protección de Riesgos Sanitarios, Mexico). It also followed the Good Clinical Practices Guidelines \[[@CR14]\], the ethical principles for medical research for humans stated in the Declaration of Helsinki \[[@CR15]\], the General Health Law of Mexico (Ley General de Salud, México) \[[@CR16]\], and the *Regulations of the General Health Law for Health Research* (Reglamento de la ley General de Salud en Materia de Investigación para la Salud, Mexico) \[[@CR17]\]. Additionally, this study was conducted according to the Mexican Official Norm (NOM-177-SSA1-2013) \[[@CR18]\].

Twenty-six Mexican subjects were included in this study and were determined as healthy by clinical and laboratory tests. All of them were informed regarding the possible risks and adverse events after taking the study product. All the volunteers gave their informed written consent to participate in the study.

Study Design {#Sec4}
------------

The study was conducted according to an open, randomized, single-dose crossover design, performed under fasting conditions. Two periods, two sequences, with a wash-out period of 7 days were used to analyze the pharmacokinetic metrics of the two products. The sample size was determined considering an expected power of 80 % and the intra-subject variability of acetaminophen reported in the literature \[[@CR19]\]. The test product was acetaminophen plus caffeine tablets of 650 mg plus 65 mg (Sedalmerck Max^®^; Merck, S.A. de C.V., Mexico \[M31344\]), whereas the reference product was acetaminophen tablets of 650 mg (Tempra^®^ Forte; Bristol-Myers Squibb de México, Mexico, S. de R.L. de C.V., Mexico \[3G100331\]), one tablet administered to the volunteers in two different periods. The sample schedule was 0.00, 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 4.00, 6.00, 8.00, 10.00, 12.00, and 24.00 h after the dose. The blood samples were obtained with heparin tubes, the plasma was separated by centrifugation (2500*g* × 5 min at 4 ± 2 °C) and stored at a temperature below −40 °C until the analysis. The safety of the subjects was monitored during the whole study.

Analytical Quantification {#Sec5}
-------------------------

The analytical procedure for the quantification of acetaminophen in plasma was developed and validated within the parameters of selectivity, precision, accuracy, linearity, and sensitivity. One hundred microliters of human plasma was added to 50 µL of internal standard (zidovudine 20 µg/mL; US Pharmacopeia reference standard, lot number HOF263). Then, 0.1 mL of formic acid (100 mM; J.T. Baker, lot number 0000071580) and 1.0 mL of ether anhydrous were added to all samples to perform a liquid-liquid extraction (J.T. Baker; lot number 0000075778) that was agitated for 2 min at 5000 rpm (Precellys^®^ 24, Bertin Corp, Rockville MD, USA). The samples were centrifuged for 5 min at 14,000 rpm at 0 °C and stored at a temperature below −70 °C. The organic phase was transferred into glass tubes (13 × 100 mm), placed in a water bath at 30 °C, and evaporated under a nitrogen current, until dry. The samples were reconstituted with 400 µL of an acetonitrile:formic acid solution (10 mM) 90:10 v/v and centrifuged at 2500 rpm for 1 min. The samples were transferred into vials for an autosampler and 5 µL was injected into the ultra-performance liquid chromatography (UPLC)-tandem mass spectrometer using a Xevo TQ-D (Waters Corp, Milford MA, USA) equipped with electrospray ionization. The UPLC was an Acquity UPLC-H Class (Waters Corp, Milford MA, USA), with a quaternary pump, an autosampler with controlled temperature, a column oven, and an in-line degasifier. The data were processed using the MassLynx 4.1 software (Waters Corp, Milford MA, USA).

The chromatographic separation was performed by a Cortecs C18 column (4.6 × 100 mm, 2.7 µm; Waters, Spain) and the mobile phase consisted of an acetonitrile:formic acid solution (10 mM) 85:15 v/v at a flow rate of 0.7 mL/min. The autosampler was kept at temperature of 6 °C, the injection volume was 5 µL, the run time for each injection was 1.5 min, and the retention times were 1.18 min for acetaminophen and 1.19 min for zidovudine. The detection was performed in positive mode by the monitoring of multiple reactions in the mass spectrometer Xevo TQ-D (Waters Corp, Milford MA, USA) Waters triple quadrupole equipped with electrospray ionization. The monitored transitions were *m*/*z* 152.0 → 110.0 for acetaminophen and *m*/*z* 268.0 → 127.0 for zidovudine. The temperature of the source was 550 °C and the voltage of the capillary was 2.4 kV. The voltage of the cone for acetaminophen was 35 V and for zidovudine was 14 V. The energy of optimal collision for acetaminophen was 15 V and for zidovudine was 8 V, argon was the collision gas employed.

Pharmacokinetics and Statistical Analysis {#Sec6}
-----------------------------------------

The pharmacokinetics of both products was determined by a non-compartmental analysis, using the Phoenix^®^ WinNonlin^®^ 6.3 Centara L.P. software, USA. The *C* ~max~ and *t* ~max~ were determined by analyzing the concentration profiles vs. time. The determination of area under the curve from time zero to the last sampling time (AUC~0--*t*~), was performed by the trapezoidal rule. The constant of elimination (*K* ~el~) was determined from the linear terminal part of the data logarithmically transformed and was estimated through a simple linear regression analysis considering at last three different concentrations from the *t* ~max~ value. It was used to determine the area under the curve from time zero to infinity (AUC~0--∞~) according to the equation: AUC~0--∞~ = AUC~0--*t*~ + *C* ~*t*~/*K* ~el~, where *C* ~*t*~ is the concentration at the last time of sampling used. The elimination half-life was determined by the ratio of In(2)/*K* ~el~. Partial AUCs were calculated at 0.5, 1.0, 1.5, 2.0, 3.0, and 4.0 h, by linear trapezoidal interpolation, which is applied to each pair of consecutive points in the data set. Only the 3.0-h time has an endpoint that was not included in the data set, thus the trapezoidal linear interpolation rule was used to add a concentration value for that endpoint.

The bioequivalence between both products was determined by calculation of the confidence intervals (CIs) at 90 % of the logarithm of the coefficient test/reference such as *C* ~max~, AUC~0--*t*~, and AUC~0--∞~ in terms of acetaminophen pharmacokinetic metrics.

Statistical analysis of the partial AUCs was by calculation of the CIs at 90 % of the logarithm of the coefficient test/reference. Analysis of variance was determined to evaluate the effects on the formulation variation, sequence, and period. Both were calculated with Phoenix^®^ WinNonlin^®^ 6.3.

Results {#Sec7}
=======

Study Population {#Sec8}
----------------

Twenty-six Mexican volunteers (five female and 21 male individuals) were included in this study, with ages between 18 and 45 years (23.9 ± 5.1 years) and a body weight between 44.2 and 82.1 kg (60.3 ± 9.3 kg). The body mass index of participants was 22.7 ± 2.3 kg/m^2^.

Validation of the Analytical Method {#Sec9}
-----------------------------------

The analytical method was linear in the range of 0.1--30 µg/mL, the best linear fit and least-squares residuals for the calibration curve were achieved with a 1/*x* ^2^ weighing factor, giving a mean linear regression equation for the calibration curve of: *y* = 1.6 *x* + 5.9 × 10^−3^, where *y* is the peak area ratio of acetaminophen to zidovudine and *x* is the concentration of the analyte. The mean correlation coefficient of the weighted calibration curve generated during the validation was 0.99.

Table [1](#Tab1){ref-type="table"} shows the results of the evaluation of precision and accuracy of the analytical method, meeting the acceptance criteria of ±15 and ±20 % of the lower limit of quantification. There were no significant matrix effects for acetaminophen or zidovudine. The stability of acetaminophen in human plasma under different temperatures was validated under the typical plasma storage and processing conditions used throughout the current study such as the autosampler temperature, room temperature, refrigeration temperature, freeze-thaw cycles, and at least 63 days of long-term storage conditions (−70 °C).Table 1Precision and accuracy of the method to determine acetaminophen in plasma samplesSampleNconc (µg/mL)Intra-day reproducibility (*n* = 6)Inter-day reproducibility (*n* = 18)Average concentration obtained (µg/mL)Accuracy (%)Precision (%)Average concentration obtained (µg/mL)Accuracy (%)Precision (%)LLOQ0.10.17.36.70.1−0.78.9LQC0.30.3−0.211.50.30.96.5MQC 13.02.85.49.22.9−2.38.2MQC 215.015.9−6.35.015.74.76.2HQC23.023.8−3.76.224.45.95.5*HQC* high quality control, *LLOQ* lower limit of quantification, *LQC* low quality control, *MQC* medium quality control, *n* total number of observations, *Nconc* nominal concentration

Pharmacokinetic Analysis {#Sec10}
------------------------

Figure [1](#Fig1){ref-type="fig"} shows the mean plasma concentrations vs. time of the arithmetic data transformed semi-logarithmically.Fig. 1Geometric mean plasma concentrations vs. time in linear scale (**a**) and semi-logarithmic scale (**b**), following the administration of the test and reference products. *Error bars* present ±1 geometric standard deviation

Results of the pharmacokinetic analysis after oral administration of 650 mg of acetaminophen (reference product) and 650 mg of acetaminophen plus 65 mg of caffeine (test product) in 25 subjects that completed the study are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Pharmacokinetics metrics of acetaminophen (*n* = 25)VariableTempra^®^ ForteSedalmerk Max^®^*C* ~max~ (µg/mL)^a^9.46 (34.21)9.72 (32.38)AUC~0--*t*~ (µg h/mL)^a^34.93 (32.58)35.89 (31.03)AUC~0--∞~ (µg h/mL)^a^36.22 (31.62)37.29 (29.52)*t* ~1/2~ (h)^b^3.77 (1.55)3.85 (1.32)*t* ~max~ ^c^1.000.75*AUC* ~*0--t*~ area under the curve from time zero to the last sampling time, *AUC* ~*0--∞*~ area under the curve from time zero to infinity, *C* ~*max*~ maximum plasma concentration, *CV* coefficient of variation, *SD* standard deviation, *t* ~*max*~ time to maximum plasma concentration, *t* ~*1/2*~ elimination half-life^a^Geometric mean (CV %)^b^Harmonic mean (jackknife SD)^c^Median

In Table [3](#Tab3){ref-type="table"}, the results of the 90 % CI of the ratio of the geometric means considering the intra-subject variability are shown. As observed, the values of the CI are within the range of acceptance (80--125 %).Table 390 % CI of *C* ~max~, AUC~0*--t*~, and AUC~0*--*∞~Pharmacokinetic metrics90 % CI of the ratio test/referenceIntra-subject CV (%)Ln *C* ~max~ (µg/mL)92.87--114.7122.0Ln AUC~0*--t*~ (µg h/mL)98.72--106.908.2Ln AUC~0*--*∝~ (µg h/mL)99.33--106.677.3*AUC* ~*0--t*~ area under the curve from time zero to the last sampling time, *AUC* ~*0--∞*~ area under the curve from time zero to infinity, *CI* confidence interval, *C* ~*max*~ maximum plasma concentration, *CV* coefficient of variation

Table [4](#Tab4){ref-type="table"} shows the results of the equivalence of partial AUCs at different time points between the two formulations. The *t* ~max~ values are shown in the boxplot in Fig. [2](#Fig2){ref-type="fig"}, evaluated by the Wilcoxon Mann--Whitney test with a significance level of α = 0.05 and a *p* value of 0.49. It shows one outlier is present in the reference product; however, it only represents an extreme value without statistical significance.Table 4Partial AUCsPartial AUCsReferenceTestPoint estimate90 % CIAUC~0*--*0.5~0.721.21169.63113.73--253.01AUC~0*--*1.0~4.065.07126.38101.30--157.67AUC~0*--*1.5~7.549.02120.63102.37--142.15AUC~0*--*2.0~10.7012.54117.98103.54--134.43AUC~0*--*3.0~16.4318.26111.53102.46--121.40AUC~0*--*4.0~20.8722.47107.82101.72--114.28*AUC* area under the curve, *CI* confidence interval Fig. 2Pharmacokinetic metric *t* ~max~ (*A* reference product, *B* test product). *t* ~*max*~ time to maximum plasma concentration

Discussion {#Sec11}
==========

The final number of evaluated subjects was 25, one volunteer was excluded because of receiving concomitant medication (hydrocortisone, loratadine, and chlorpheniramine) for the treatment of a non-serious adverse event not related to the study (food allergy). Another volunteer had a flu condition, with a total of two non-serious adverse events during the study (the last volunteer finished the trial).

The method showed good precision and accuracy. Table [1](#Tab1){ref-type="table"} summarizes the intra- and inter-day precision and accuracy values for acetaminophen from quality-control samples. In this assay, the intra- and inter-assay precisions were measured to be below 5.0 and 11.5 %, respectively, with relative errors from −6.3 to 7.3 %. These values were within the acceptable range, and the method was thus judged to be suitably accurate and precise. Under the present low limit of quantification of 0.1 ng/mL, this is sensitive enough to investigate the pharmacokinetic behavior of acetaminophen in clinical studies.

The pharmacokinetic analysis showed no differences in the absorption rate and bioavailability of the drug to reach the bloodstream. Table [2](#Tab2){ref-type="table"} shows the geometric mean *C* ~max~ values of 9.46 and 9.72 µg/mL for the reference and test products, respectively. The geometric mean AUC~0--*t*~ values were 35.89 h µg/mL and AUC~0--∞~ 37.29 h µg/mL for the reference product, while for the test product the values were 34.93 and 36.22 h µg/mL, respectively. These values demonstrated that the bioavailability of the drug in both formulations did not present differences, which was confirmed with the results in Table [3](#Tab3){ref-type="table"}. Indeed, at a 90 % CI (range 80--125 %), the bioequivalence was demonstrated. The intra-subject variability obtained was of 22.0 % for *C* ~max~, 8.2 % for AUC~0--*t*~, and 7.3 % for AUC~0--∞~ (Table [3](#Tab3){ref-type="table"}), demonstrating that acetaminophen in both formulations presents a low variability in the Mexican population.

Table [4](#Tab4){ref-type="table"} shows the statistical analysis of the partial AUCs determined at different times. The partial AUCs from 0 to 2.0 h show differences because they are not contained in the 90 % CI range (80--125 %) and there is high variability in the results. This denotes higher values for the test product than the reference product. This behavior is related to differences in absorption that were present only during the period from time zero until 120 min post-dose. They can be attributed to the presence of caffeine, according to the investigation performed by Renner et al. \[[@CR19]\], where it was demonstrated that caffeine presence assures the rapid absorption of acetaminophen. Moreover, another study, which compared the administration of conventional acetaminophen tablets with effervescent tablets, showed that there is also a modification in *t* ~max~, suggesting that changes in the conditions of the media in which acetaminophen is dissolved favor its rapid absorption \[[@CR20]\]. Assuming that the products used in this clinical trial had no differences between formulations (both are immediate-release tablets, without film, enteric, or sugar coatings), the difference is that the test product contains acetaminophen plus caffeine while the reference product only contains acetaminophen.

The *t* ~max~ was evaluated by the Wilcoxon Mann--Whitney test, obtaining a *p* value of 0.49 (*p* \> 0.05), demonstrating there are no statistical differences in the *t* ~max~ value between both formulations. For this reason, the *C* ~max~ did not suffer modification because *t* ~max~ is not an adequate indicator of the absorption rate \[[@CR20]\]. It was expected to observe differences in the pharmacokinetics with the presence of caffeine, as indicated by Renner et al. \[[@CR19]\]. Indeed, in this study, the 90 % CI of partial AUCs allowed us to evaluate the difference in the plasma concentrations of acetaminophen, showing that the bioavailability and absorption rate of acetaminophen with the test product was greater than the reference product, only in the first minutes. This determination was based on the US Food and Drug Administration guidelines, "Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: General Considerations" \[[@CR21]\], which recommend the determination of "early exposure" to evaluate the information regarding the appropriate clinical efficacy/safety in pharmacokinetic/pharmacodynamic studies.

Conclusions {#Sec12}
===========

With the results obtained it was concluded that the test product is bioequivalent to the reference formulation in terms of rate and bioavailability of acetaminophen because the 90 % CIs are within the acceptance range of 80--125 %. It was also concluded that the determination of the 90 % CI of partial AUCs is more sensitive to establish the degree of absorption of a drug in the first hours following its oral administration than the statistical analysis of *t* ~max~. However, it has be used with more than three sampling points before *t* ~max~ and requires extreme sample sizes owing to its high variability. In the Mexican population studied, the test product is absorbed slightly faster than the reference product, thus an analgesic effect can be expected in a shorter period of time, which represents an advantage in the management of acute pain.
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